Sensitivity, specificity, PPV, and NPV for the cumulative DAS28-CRP and total PD score to predict nonradiographic progression.
| Treatment Regimen | Disease Activity Measures | Cutoff (average) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|
| Total, n = 57 | DAS28-CRP | < 9.0 (3.0) | 64 | 81 | 85 | 57 |
| Total GS score | < 62 (20.7) | 56 | 57 | 69 | 43 | |
| Total PD Sore | < 21 (6.8) | 69 | 76 | 83 | 59 | |
| MTX, n = 16 | DAS28-CRP | < 10.8 (3.6) | 89 | 71 | 80 | 83 |
| Total GS score | < 60 (20.0) | 78 | 43 | 64 | 60 | |
| Total PD Sore | < 20 (6.5) | 89 | 86 | 86 | 89 | |
| TNF antagonist, n = 24 | DAS28-CRP | < 11.9 (4.0) | 88 | 71 | 88 | 71 |
| Total GS score | < 70 (23.3) | 65 | 57 | 79 | 40 | |
| Total PD Sore | < 21 (6.8) | 65 | 71 | 85 | 46 | |
| TCZ, n = 17 | DAS28-CRP | < 9.0 (3.0) | 80 | 71 | 80 | 71 |
| Total GS score | < 62 (20.7) | 60 | 71 | 75 | 56 | |
| Total PD Sore | < 18 (6.0) | 70 | 86 | 88 | 67 |
PPV: positive predictive value; NPV: negative predictive value; DAS28: 28-joint Disease Activity Score; CRP: C-reactive protein; GS: greyscale; PD: power Doppler; MTX: methotrexate; TNF: tumor necrosis factor; TCZ: tocilizumab.